Estudo do NATS contribui para inclusão de novos imunoterápicos no SUS

Simple item page
dc.TypeArticlept_BR
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva
dc.contributor.authorInstituto Nacional de Câncer (Brasil)
dc.contributor.authorINCA
dc.date.accessioned2022-03-30T19:24:50Z
dc.date.available2022-03-30T19:24:50Z
dc.date.issued2020-09
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/6177
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.subjectNivolumabept_BR
dc.subjectNivolumabpt_BR
dc.titleEstudo do NATS contribui para inclusão de novos imunoterápicos no SUSpt_BR
dc.title.alternativeInforme INCA 399pt_BR

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Informe-INCA-2020-399-4-Estudo-do-NATS.pdf
Size:
230.79 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informe INCA 399